Seqcureneo
Advancing cancer immunotherapies.
SeqCure Immunology is a Stockholm-based immunotherapy startup that develops SeqCureNEO, a curative, personalized cell therapy for treatment of advanced-stage cancer.
About seqcure.
Personalized cell therapy - for all cancers.
SeqCure Immunology is a Stockholm-based company that develops SeqCureNEO, a personalized cell therapy product for the treatment of advanced-stage cancer.
The SeqCureNEO cell product is created from the patient's own immune cells, isolated from a blood sample. Through our proprietary culturing process, the cells are cultured and modified to react against the patient's individual tumor mutations. No genetic engineering - only enrichment and strengthening of the weak anti-tumor immune response that already exists in the patient.
SeqCure Immunology is currently seeking investors to fund the final pre-clinical developement of SeqCureNEO in preparation for its First-In-Man clinical trial.
NEWS.
SeqCureselected to present at the Nordic Innovation Fair.
2021-09-01
Our concept.
SeqCureNEO - specificity and potency combined.
Every human is unique, and so is every tumor. SeqCureNEO is a personalized cell therapy product, tailor-made from the mutation profile of each individual patient. From a blood sample, immune cells are isolated, stimulated, enriched, cultured - and returned to the patient. Our proprietary manufacturing process ensures that only the tumor-reactive cells are allowed to grow, thereby maintaining specificity and potency while minimizing side effects.
1. Sampling of blood and tumor tissue.
In order to identify tumor-driving mutations, small samples of blood and tumor are needed.
If tumor tissue samples have been stored from previous surgery and/or biopsy sampling, those samples may be used in this step, alleviating the need for additional invasive procedures.
2. Deep sequencing.
From the blood- and tumor tissue samples, DNA and RNA are extracted and analysed using deep sequencing technology.
1. Sampling of blood and tumor tissue.
In order to identify tumor-driving mutations, small samples of blood and tumor are needed.
If tumor tissue samples have been stored from previous surgery and/or biopsy sampling, those samples may be used in this step, alleviating the need for additional invasive procedures.
2. Deep sequencing.
From the blood- and tumor tissue samples, DNA and RNA are extracted and analysed using deep sequencing technology.
2. Bioinformatic analys and neoantigen prediction.
Using advanced bioinformatic algorithms, the patient's unique tumor-driving mutations are identified from the DNA- and RNA sequences analysed in the previous step.
4. Neoantigen synthesis.
Neoantigen peptides (small proteins) that correspond to the identified tumor-driving mutations are produced.
.png)
5. Cell expansion.
From a blood sample, immune cells are isolated and expanded in a cleanroom laboratory. During this phase, the cells are enriched and carefully monitored to ensure that potency as well as anti-tumor specificity is maintained throughout the culture.
5. Cell expansion.
Following purification and rinsing, the SeqCureNEO cell product is now ready to be administered to the patient. The transfer procedure is similar to an ordinary blood transfusion.
1. Sampling of blood and tumor tissue.
In order to identify tumor-driving mutations, small samples of blood and tumor are needed.
If tumor tissue samples have been stored from previous surgery and/or biopsy sampling, those samples may be used in this step, alleviating the need for additional invasive procedures.
2. Deep sequencing.
From the blood- and tumor tissue samples, DNA and RNA are extracted and analysed using deep sequencing technology.
3. Bioinformatic analysis and neo-antigen prediction
Using advanced bioinformatic algorithms, tumor-driving mutations are identified from the DNA- and RNA sequences.
4. Peptide synthesis.
Neo-antigenic peptides (small proteins) that correspond to the identified tumor-driving mutations are produced.
5. Cell culture
From an additional small blood sample, immune cells are isolated and expanded in a clean room laboratory. During the cell expansion, the tumor-reactive cells grow in numbers from tens of thousands up to several billions. The previously synthesized neo-antigenic peptides are used during this step to ensure that the growing cells are stimulated to be reactive against the tumor.
6. Cell infusion
Following the expansion phase, the cells are purified and washed prior to transfer of the cell product to the patient. The transfer procedure is similar to an ordinary blood transfusion.
We are located at the Karolinska Institutet
SeqCure Immunology is a member of the KI Innovations DRIVE incubator. Our lab and main office are located on the Karolinska Institutet campus area in Stockholm, Sweden.
Get in touch with the team
Want to learn more about SeqCureNEO?
Fill out the form below (or send us an email) and we will get back to you shortly.
.png){kind=spacer}
